The main purpose of the study is to assess how well the standard ablation procedure (Varipulse Catheter) works over long term when used with different types of anesthesia in participants with symptomatic paroxysmal atrial fibrillation (PAF, irregular heartbeat that comes and goes on its own, causing noticeable symptoms like a racing heart, or shortness of breath).
Official registry: https://clinicaltrials.gov/study/NCT07511166 · Johnson & Johnson Medical (Shanghai) Ltd. · enrollment listed as 300
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 300 people at Shanghai. Taking part typically means study visits and measurements plus check-ins.
High-quality Pulmonary Veins Isolation Using Varipulse Catheter Under Contact and Continuity Guidance in Patients With Paroxysmal Atrial Fibrillation Under Optimized Sedation
Primary outcome (registry wording): Freedom From Documented (Symptomatic and Asymptomatic) Atrial Tachyarrhythmias Episode
YanTing Zhang
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This is a single-center prospective watch-and-measure (no experimental treatment required) cohort study of atrial fibrillation patients treated with radiofrequency ablation.
NCT05266144 · Official ClinicalTrials.gov record · Peking Union Medical College Hospital
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm.
NCT05724121 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
REACT-AF is a multicenter prospective, randomly assigned, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
NCT05836987 · Official ClinicalTrials.gov record · Johns Hopkins University
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary